Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.42 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10622242 | 0.86 | HSD17B10 (0.53) | HSD17B10GAANPSR1ALDH1A1TSHR | |
| SCHEMBL7625417 | 0.86 | MEN1 (0.41) | HSD17B10GAAALDH1A1CLCN2MEN1 | |
| SCHEMBL3625212 | 0.85 | HSD17B10 (0.51) | HSD17B10GAANPSR1ALDH1A1TSHR | |
| SCHEMBL11198865 | 0.84 | CXCL8 (0.53) | HSD17B10GAATDP1CXCL8MEN1 | |
| SCHEMBL480112 | 0.84 | MEN1 (0.44) | HSD17B10ALDH1A1CLCN2MEN1KMT2A | |
| SCHEMBL11111891 | 0.83 | POLB (0.50) | HSD17B10NPSR1CLCN2POLBSMN1; SMN2 | |
| SCHEMBL10727224 | 0.82 | POLB (0.39) | HSD17B10GAANPSR1ALDH1A1TDP1 | |
| SCHEMBL11706103 | 0.81 | POLB (0.42) | HSD17B10CLCN2POLBSMN1; SMN2 | |
| SCHEMBL7628064 | 0.80 | MEN1 (0.41) | HSD17B10GAAALDH1A1TSHRCLCN2 | |
| SCHEMBL18716699 | 0.79 | POLB (0.47) | NPSR1ALDH1A1CLCN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1011651-B1 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6451734-B1 | Substituted 3-benzylpyrazoles and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-1011651-A4 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | MERCK & CO INC (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-1011651-A1 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | Merck & Co., Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| US-6020382-A | Method of treating diabetes and related disease states | MERCK & CO., INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-5847008-A | Method of treating diabetes and related disease states | MERCK & CO., INC. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1997027847-A1 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| EP-0106565-B1 | LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION, AND COMPOSITIONS CONTAINING THEM | MERCK FROSST CANADA INC. (CA) | 1986-09-10 | — | — | EP | disclosed |
| EP-0106565-A1 | Leukotriene antagonists, their production, and compositions containing them | MERCK FROSST CANADA INC. (CA) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | HSD17B10 1321/4885GAA 15/4885NPSR1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.